Abstract 10P
Background
The golden standard for evaluating the effect of neoadjuvant chemotherapy（NACT）in breast cancer is the pathological response of the surgery——pathologic Complete Response (pCR). Thymidine kinase 1 (TK1) is one of the key enzymes in DNA synthesis, and its serum concentration can indirectly reflect tumor proliferation.At present, TK1 has shown value in the diagnosis and prognosis assessment of various cancers, but there are few reports on the predictive value of NACT for breast cancer. The aim of this study was to research whether serum thymidine kinase levels could be used for early prediction of pathological responses to NACT in HER2-negative breast cancer.
Methods
Clinical characteristics, pathological information, and serum TK1 data during NACT of HER2-negative breast cancer patients receiving 6 or 8 cycles of anthracycline/paclitaxel neoadjuvant chemotherapy in Yunnan Cancer Hospital from January 1, 2022 to June 30, 2023 were retrospectively collected. The differences of the above data between the pCR group and the non-pCR group were compared and analyzed, and logistic regression analysis was used to explore whether serum TK1 could be used as one of the independent predictors of pCR.
Results
155 patients with HER2-negative breast cancer were retrospectively included. According to postoperative pathological information, they were divided into pCR group and non-pCR group. There were significant differences in ER (P < 0.001), PR(P=0.001), Ki67 (P=0.025), sTK1 at baseline (P=0.001),and Average level of sTK1 during NACT(P=.016) between the two groups. Multivariate logistic regression analysis of the above factors showed that: Lower sTK1 at baseline (0R=0.067, 95%CI 0.010-0.444, P=0.005) and lower Average level of sTK1 during NACT (0R=0.093,95%CI 0.010-0.895, P=0.04) were associated with greater likelihood of reaching pCR.
Conclusions
The baseline level of sTK1 before treatment and the average level of sTK1 during NACT can be used as an independent predictor of reaching pCR after NACT for HER2-negative breast cancer. The ease of obtaining serial measurements makes TK1 is expected to be an important tool to evaluate the efficacy and prognosis of breast cancer.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Yunnan Province Education Department.
Disclosure
All authors have declared no conflicts of interest.